Damian Kovalovsky, Ph.D.
Dr. Kovalovsky directs the Branch's T-Cell Engineering Facility, providing support for the pre-clinical development of new T-cell therapies and analysis of several research endpoints related to the immune response in ongoing immunotherapy clinical trials.
1) hematopoietic differentiation, 2) T-cell response, 3) immunology
The T-Cell Engineering Facility provides support for the development and implementation of novel immunotherapies as well as the analysis of immune endpoints in ongoing clinical trials.
Selected Key Publications
- Oncotarget. 7: 58768-58778, 2016. [ Journal Article ]
Zbtb1 safeguards genome integrity and prevents p53-mediated apoptosis in proliferating lymphoid progenitors.J Immunol. 197: 1199-211, 2016. [ Journal Article ]
- J Immunol. 195: 4273-81, 2015. [ Journal Article ]
PLZF induces the spontaneous acquisition of memory/effector functions in T cells independently of NKT cell-related signals.J Immunol. 184: 6746-55, 2010. [ Journal Article ]
The BTB-zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions.Nat Immunol. 9: 1055-64, 2008. [ Journal Article ]
Dr. Kovalovsky received his Ph.D from the University of Buenos Aires, Argentina. He obtained postdoctoral training at the Molecular Oncology Research Institute, Tufts-New England Medical Center and at Memorial Sloan Kettering Cancer Center, where he studied the mechanisms of negative selection of thymocytes as well as the differentiation of iNKT cells. Before joining the Experimental Transplantation and Immunology Branch, he was an investigator in the Experimental Immunology Branch where he studied the transcription factors controlling the differentiation of hematopoietic progenitors and T-cells.
|Samantha Simon Ph.D.||Biologist (Contr.)|
|Elisaveta Voynova Ph.D.||Scientist (Contr.)|